Contrave for Weight Loss: How It Works, Dosing, and Natural Stacks

What Is Contrave and How Does It Work for Weight Loss?

Contrave is an FDA-approved prescription combination of naltrexone HCl (8 mg) and bupropion HCl (90 mg) in an extended-release formulation. The target daily dose is two tablets twice daily — 32 mg naltrexone / 360 mg bupropion — reached after a four-week titration. Bupropion is a dopamine and norepinephrine reuptake inhibitor originally approved for depression and smoking cessation; naltrexone is an opioid receptor antagonist used in addiction medicine. Together they act on the hypothalamic pro-opiomelanocortin (POMC) neurons and mesolimbic reward pathways to reduce appetite and blunt food cravings.

The COR-I pivotal trial (Greenway et al., Lancet 2010; PMID: 20673995) randomized 1,742 adults with obesity to Contrave or placebo for 56 weeks. At full dose, participants lost an average of 6.1% of body weight vs. 1.3% for placebo — a meaningful but modest effect. Crucially, ~40% of Contrave-treated participants discontinued before week 56, most commonly due to nausea, constipation, headache, or elevated blood pressure. That real-world dropout profile matters enormously when planning any weight-loss strategy.

Contrave does not affect insulin sensitivity or lipid panels directly, nor does it address the metabolic drivers — chronic inflammation, mitochondrial dysfunction, elevated cortisol — that often underlie diet-resistant weight gain.

Bioavailability Considerations: Why Contrave's Absorption Matters

Bupropion's oral bioavailability is approximately 5–20% due to extensive first-pass metabolism; the extended-release matrix in Contrave smooths peak plasma levels and reduces seizure risk, which increases with rapid dose escalation. Naltrexone's bioavailability is roughly 5–40%, highly variable between individuals depending on CYP2D6 polymorphisms and gut transit time.

A critical prescribing note: taking Contrave with a high-fat meal increases bupropion peak plasma concentration (Cmax) by up to 29% and AUC by 19% — enough to raise seizure risk. The label explicitly instructs patients to avoid high-fat meals at dosing time. This creates an ironic behavioral constraint for anyone trying to follow a ketogenic or high-fat Mediterranean-style diet while on Contrave.

For people pursuing metabolic improvement alongside weight loss, these bioavailability quirks underscore why individualized nutrition context — not just a pill — drives outcomes. A personalized supplement plan that accounts for your diet pattern and metabolic labs is one way to close that gap.

Alpha Lipoic Acid for Weight Loss: Stack Potential With or Without Contrave

Alpha lipoic acid (ALA) is a mitochondrial cofactor and potent antioxidant that has generated genuine clinical interest as a metabolic adjunct. A 2011 randomized controlled trial (Koh et al., Obesity Reviews; PMID: 21951506) found that 1,800 mg/day of ALA over 20 weeks produced modest but statistically significant reductions in body weight and waist circumference compared to placebo in overweight adults. The proposed mechanisms include AMPK activation, improved insulin sensitivity, and reduced hypothalamic oxidative stress — mechanisms that work upstream of, and complementarily to, Contrave's central appetite suppression.

At a practical level, ALA stack timing matters. Because ALA chelates heavy metals and can transiently lower blood glucose, it should be taken away from other antioxidants and timed with meals. In the context of Contrave, there is no known pharmacokinetic interaction, but anyone combining them should monitor blood pressure and fasting glucose. Standard supplemental doses range from 300–600 mg for the R-ALA form (equivalent to 600–1,200 mg racemic ALA).

The AMPK-activating pathway is shared by several other natural compounds, which brings us to a consistently underappreciated molecule.

Pterostilbene for Weight Loss: The Bioavailable Polyphenol Contrave Misses

Pterostilbene is a dimethylated analog of resveratrol found in blueberries and Pterocarpus marsupium heartwood. Its oral bioavailability is dramatically higher than resveratrol — approximately 80% vs. 20% — because the two methyl groups resist rapid glucuronidation and sulfation. This translates to a longer plasma half-life (roughly 105 minutes vs. 14 minutes for resveratrol) and clinically meaningful tissue exposure at supplemental doses of 50–250 mg/day.

For weight management, pterostilbene activates PPAR-alpha (promoting fat oxidation), inhibits fatty acid synthase, and upregulates SIRT1 — the same longevity-linked deacetylase activated by caloric restriction (Rimando et al., Journal of Agricultural and Food Chemistry 2005; PMID: 16190627). A 2012 human pilot study found that 125–250 mg/day of pterostilbene over eight weeks improved lipid profiles and modestly lowered body weight in hypercholesterolemic adults (Riche et al., Evidence-Based Complementary and Alternative Medicine; PMID: 23304218).

Critically, pterostilbene's anti-inflammatory and lipid-modulating effects can support the metabolic improvements that Contrave alone does not address. If your lipid numbers haven't budged despite weight-loss efforts, understanding how long it takes to lower LDL particle number can help set realistic expectations and inform which stack ingredients to prioritize. You can also explore a dedicated pterostilbene dosing guide for more on bioavailability-optimized forms.

Sulforaphane for Weight Loss: Epigenetic Leverage Contrave Doesn't Touch

Sulforaphane, the isothiocyanate derived from glucosinolate precursors in cruciferous vegetables (particularly broccoli sprouts), operates through an entirely different molecular layer than Contrave. Its primary mechanism is Nrf2 pathway activation — upregulating the body's endogenous antioxidant and detoxification enzymes, including glutathione-S-transferase and heme oxygenase-1. This matters for weight loss because chronic low-grade inflammation and oxidative stress are independent drivers of adipogenesis and insulin resistance.

A 2012 randomized trial in obese patients with type 2 diabetes found that sulforaphane supplementation (from broccoli sprout extract, standardized to ~10 µmol/day sulforaphane equivalents) significantly reduced fasting blood glucose and HbA1c over 4 weeks compared to placebo (Bahadoran et al., Journal of Diabetes & Metabolic Disorders; PMID: 23497654). While this was a glucose-focused trial, improved insulin sensitivity has downstream benefits for adipose tissue mobilization — a mechanism Contrave does not address.

Sulforaphane's bioavailability is also variable and highly dependent on the presence of the myrosinase enzyme. Fresh broccoli sprouts deliver active sulforaphane directly; dried broccoli powder supplements without added myrosinase may yield far less. Standardized sprout extracts or myrosinase-containing supplements at 10–100 µmol equivalents daily represent the clinically rational dose range.

For people with metabolic syndrome markers — elevated triglycerides, high A1C, or poor glucose control — combining sulforaphane's Nrf2 activation with Contrave's appetite suppression creates a genuinely complementary stack. If your A1C is part of the picture, understanding what A1C actually measures is a useful starting point before selecting metabolic adjuncts.

Urolithin A for Weight Loss: Mitochondrial Renewal as a Hidden Lever

Urolithin A (UA) is a gut-microbiome-derived metabolite produced from ellagitannins found in pomegranates, walnuts, and raspberries. The conversion requires specific gut bacteria — Gordonibacter pamelaeae and Gordonibacter urolithinfaciens — that roughly 30–40% of adults lack, making dietary intake alone insufficient for most people. Supplemental UA at 500–1,000 mg/day bypasses this metabolic gap.

UA's primary mechanism relevant to weight management is mitophagy — the selective clearance of dysfunctional mitochondria. Accumulated mitochondrial debris impairs cellular energy efficiency, contributing to fatigue and reduced fat oxidation capacity. A 2022 randomized controlled trial (Liu et al., Nature Aging; PMID: 35761078) demonstrated that 500 mg/day of urolithin A over four months significantly improved mitochondrial gene expression, muscle endurance, and plasma acylcarnitine profiles in middle-aged adults — markers of enhanced mitochondrial function without caloric restriction or structured exercise.

For someone on Contrave, improved mitochondrial efficiency means more cellular energy available for fat oxidation during the modest physical activity most people attempt alongside pharmacotherapy. UA is not a stimulant and has no known interaction with naltrexone or bupropion, making it a low-risk addition to a Contrave protocol.

Urolithin A also exhibits meaningful anti-inflammatory effects, partially via NF-κB inhibition, reinforcing sulforaphane's Nrf2-mediated anti-inflammatory layer. The synergy between these two mechanisms is additive, not redundant.

How Ones Addresses This

Contrave works at the level of neurotransmitter signaling — a valuable but narrow intervention. The metabolic drivers that often blunt weight-loss drug efficacy (mitochondrial dysfunction, systemic inflammation, insulin resistance, oxidative stress) require a different toolkit.

Ones uses lab results, wearable data, and health history to build custom daily capsule formulas. For someone in a weight-loss protocol — whether using Contrave or not — the Ones AI considers several relevant ingredients:

• Pterostilbene is included in Ones formulas at clinically relevant doses informed by the Riche et al. and Rimando et al. trial data. Its PPAR-alpha and SIRT1 activation complements the central appetite suppression that medications like Contrave provide, addressing lipid metabolism and fat oxidation that drugs alone miss.
• Ones' Liver Support System Blend incorporates compounds that support Phase I and Phase II detoxification — particularly relevant for individuals on bupropion, which is heavily hepatically metabolized via CYP2B6. Supporting liver function can help maintain consistent bupropion clearance and reduce metabolite accumulation.
• Omega-3 (EPA/DHA) at clinical doses addresses the triglyceride and inflammatory picture that frequently accompanies weight-related metabolic dysfunction, providing a well-documented complement to any weight management protocol (Mori et al., American Journal of Clinical Nutrition 2003; PMID: 12600850).

None of these replace medical supervision or the clinical decision to use or discontinue Contrave. Ones formulas are designed to work alongside, not instead of, appropriate medical care.

Key Takeaways

• Contrave (naltrexone/bupropion ER) produces modest but real weight loss (~6% body weight) in clinical trials, with a ~40% dropout rate due to side effects — making complementary metabolic support important for sustainability.
• Contrave's bioavailability is diet-sensitive; high-fat meals increase bupropion Cmax and should be avoided at dosing time, which constrains popular dietary patterns like keto.
• Alpha lipoic acid (300–600 mg R-ALA) activates AMPK and improves insulin sensitivity — a mechanistically distinct and complementary layer to Contrave's central appetite suppression.
• Pterostilbene's ~80% oral bioavailability and PPAR-alpha/SIRT1 activation make it a superior polyphenol choice for supporting fat oxidation and lipid improvement alongside any weight-loss protocol.
• Sulforaphane (10–100 µmol/day from myrosinase-active sources) addresses Nrf2-mediated inflammation and insulin resistance — metabolic terrain Contrave does not reach.
• Urolithin A (500–1,000 mg/day) improves mitochondrial quality and fat oxidation capacity via selective mitophagy, offering a cellular energy advantage that amplifies results from diet and pharmacotherapy.

Always consult a qualified healthcare provider before starting, adjusting, or discontinuing prescription medications like Contrave. Supplements discussed here are not intended to diagnose, treat, cure, or prevent any disease.